The Natural History of Lone Atrial Flutter

Halligan, Sean; Gersh, Bernard J.; Brown, Robert D.; Rosales, A. Gabriela; Munger, Thomas M.; Shen, Win Kuang; Hammill, Stephen C.; Friedman, Paul A.

doi:10.7326/0003-4819-140-4-200402170-00008

Cited by 128 publications

(85 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Częstość występowania trzepotania przedsionków wynosi mniej niż 1/10 częstości występowania AF [159]. Trzepotanie przedsionków często współistnieje z AF lub je poprzedza [160]. W przypadku typowego trzepotania zależnego od cieśni załamki P często mają morfologię "zębów piły", zwłaszcza w odprowadzeniach znad ściany dolnej (II, III, aVF).…”

Section: Elektrokardiograficzne Wykrywanieunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,379

4,206

View full text Add to dashboard Cite

Section: Elektrokardiograficzne Wykrywanieunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,379

4,206

View full text Add to dashboard Cite

“…159 Atrial flutter often coexists with or precedes AF. 160 In typical, isthmus-dependent flutter, P waves will often show a 'saw tooth' morphology, especially in the inferior leads (II, III, aVF). The ventricular rate can be variable (usual ratio of atrial to ventricular contraction 4:1 to 2:1, in rare cases 1:1) and macro-re-entrant tachycardias may be missed in stable 2:1 conduction.…”

Section: Electrocardiogram Detection Of Atrial Fluttermentioning

confidence: 99%

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof¹,

Benussi²,

Kotecha³

et al. 2016

Eur J Cardiothorac Surg

913

625

View full text Add to dashboard Cite

“…7 Atrial flutter (AFL) is less prevalent than AF, but it frequently leads to AF and is associated with a similar increase in the risk of stroke. 8,9 Not surprisingly, the costs of managing AF are substantial, with annual costs estimated at $4700 per patient 10 or $6.65 billion across the United States, 11 largely driven by inpatient hospital admissions. 11,12 Although effective treatments are available to maintain and restore sinus rhythm in AF/AFL patients, 13 these have had little impact on hospitalization rates, which have tended to rise year-on-year.…”

Section: Introductionmentioning

confidence: 99%

Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA‐Like Patients With Atrial Fibrillation/Atrial Flutter in the United States

Naccarelli

Johnston

Lin

et al. 2010

Clinical Cardiology

View full text Add to dashboard Cite

Background: The ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter) demonstrated that dronedarone reduced the risk of cardiovascular (CV) hospitalization/death by 24% (P < 0.001) in patients with atrial fibrillation (AF) and atrial flutter (AFL). Hypothesis: In order to estimate the cost savings associated with dronedarone use, we estimated the costs associated with CV hospitalizations and inpatient mortality in a large cohort of ATHENA-like patients. Methods: In this retrospective analysis, we evaluated the cost of CV hospitalization/mortality in real-world ATHENA-like patients without heart failure and with employer-sponsored Medicare supplemental insurance in the United States. Patients similar to those in ATHENA (age ≥70 years with AF/AFL and ≥1 stroke risk factor, without heart failure) who were hospitalized between January 2, 2005, and January 1, 2007, were identified from the MarketScan databases from Thomson Reuters. Health care costs were evaluated during the 12 months following the index hospitalization. Results: The analysis included 10 200 ATHENA-like patients.Hospitalization for CV causes occurred in 53.9% of patients, with a total of 6700 CV hospitalizations for fatal/nonfatal causes. The most common nonfatal causes of CV hospitalizationswere AF/other supraventricular rhythm disorders (20.2% of all CV hospitalizations),congestive heart failure (CHF; 14.3%), and transient ischemic attack (TIA)/stroke (10.7%). Mean costs per CV hospitalization for nonfatal causes were $10908. Inpatient deaths from CV causes occurred in 264 (2.6%) patients; the most common causes of CV inpatient death were intracranial/gastrointestinal hemorrhage (24.2% of CV deaths), TIA/stroke (17.0%), and CHF (15.9%). Mean hospitalizationcosts per CV inpatient death were $18 565. Conclusions: Health care costs associated with CV hospitalizations and inpatient deaths among ATHENA-like patients in the US are high. Novel antiarrhythmic therapies such as dronedarone, with the potential to reduce CV hospitalizations/mortality in similar patients, could decrease health care costs if adopted in clinical practice.

show abstract

The Natural History of Lone Atrial Flutter

Cited by 128 publications

References 6 publications

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA‐Like Patients With Atrial Fibrillation/Atrial Flutter in the United States

Contact Info

Product

Resources

About